Scientists peek inside skin to see how eczema drug works
NCT ID NCT03293030
Summary
This study aimed to understand how the approved eczema medication dupilumab changes the immune environment and gene activity in the skin over time. Seventeen adults with moderate-to-severe eczema received dupilumab injections for a year. Researchers took small skin samples to analyze immune cells and genes before and during treatment to link these biological changes to how well patients' eczema improved.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSF Psoriasis and Skin Treatment Center
San Francisco, California, 94118, United States
Conditions
Explore the condition pages connected to this study.